The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A GINECO phase I study evaluating lenalidomide (Le) combined with pegylated liposomal doxorubicin (PLD) and carboplatin (C) in late (>6 months) recurrent ovarian cancer (LROC) patients (pts).
 
Frédéric Selle
Honoraria - MSD; PharmaMar; Roche Pharma AG
Consulting or Advisory Role - PharmaMar; Roche Pharma AG
Travel, Accommodations, Expenses - MSD; PharmaMar; Roche Pharma AG
 
Anne Lesoin
No Relationships to Disclose
 
Marie-Christine Kaminsky
No Relationships to Disclose
 
Philippe Follana
No Relationships to Disclose
 
Isabelle Ray-Coquard
Research Funding - PharmaMar; Roche Pharma AG
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Roche Pharma AG
 
Dominique Berton-Rigaud
No Relationships to Disclose
 
Anne Floquet
Consulting or Advisory Role - MSD Oncology; Roche
Travel, Accommodations, Expenses - GlaxoSmithKline; MSD Oncology; Roche
 
Anne-Claire Hardy-Bessard
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Novartis; PharmaMar; Roche Pharma AG
Travel, Accommodations, Expenses - Novartis; PharmaMar; Roche Pharma AG
 
Florence Joly
Travel, Accommodations, Expenses - Novartis
 
Eric Pujade-Lauraine
Honoraria - AstraZeneca; Roche Pharma AG